• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Parkinson's disease epidemiology in the Northampton District, England, 1992.

作者信息

Sutcliffe R L, Meara J R

机构信息

St. Andrew's Hospital, Northampton, England.

出版信息

Acta Neurol Scand. 1995 Dec;92(6):443-50. doi: 10.1111/j.1600-0404.1995.tb00478.x.

DOI:10.1111/j.1600-0404.1995.tb00478.x
PMID:8750108
Abstract

In a population of 302,000, in a Midlands district of England, the estimated prevalence of idiopathic Parkinson's disease (IPD) increased from 108 to 121 per 100,000 from 1982 to 1992. Individual general practice prevalence ranged quite widely. Webster ratings were significantly more often scored in 1992, but at a lower level of severity, suggesting earlier diagnosis. Incidence in 1992 was estimated as 12 per 100,000 per annum. Micrographia, when copying interlocking pentagons, was significantly related to Hoehn & Yahr scores. Over the 10-year period, there has been a considerable change in prescribing: a positive response to medication was confirmed as a good diagnostic indicator. Progression of symptoms and an increase of physical disability was noted in those of the 1982 study alive in 1992.

摘要

相似文献

1
Parkinson's disease epidemiology in the Northampton District, England, 1992.
Acta Neurol Scand. 1995 Dec;92(6):443-50. doi: 10.1111/j.1600-0404.1995.tb00478.x.
2
Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.左旋多巴、甲基丙二酸和特发性帕金森病的神经病变。
Ann Neurol. 2010 Jul;68(1):28-36. doi: 10.1002/ana.22021.
3
Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability.英国北安普敦卫生局辖区内的帕金森病。患病率与残疾情况研究。
Acta Neurol Scand. 1985 Oct;72(4):363-79. doi: 10.1111/j.1600-0404.1985.tb00886.x.
4
Levodopa-dyskinesia incidence by age of Parkinson's disease onset.帕金森病发病年龄对应的左旋多巴诱导的异动症发生率
Mov Disord. 2005 Mar;20(3):342-4. doi: 10.1002/mds.20360.
5
Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients.帕金森病的药物处方模式:一项针对非卧床患者队列的药物流行病学调查。
Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):149-57. doi: 10.1002/pds.682.
6
Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.罗匹尼罗治疗早期帕金森病:一项为期5年的左旋多巴对照研究的6个月中期报告。056研究组
Mov Disord. 1998 Jan;13(1):39-45. doi: 10.1002/mds.870130111.
7
Serum methylmalonic acid correlates with neuropathic pain in idiopathic Parkinson's disease.血清甲基丙二酸与特发性帕金森病的神经病理性疼痛相关。
Neurol Sci. 2017 Oct;38(10):1799-1804. doi: 10.1007/s10072-017-3056-9. Epub 2017 Jul 19.
8
Polyneuropathy in levodopa-treated Parkinson's patients.左旋多巴治疗的帕金森病患者的多发性神经病
J Neurol Sci. 2016 Dec 15;371:36-41. doi: 10.1016/j.jns.2016.09.061. Epub 2016 Oct 2.
9
Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.
J Neural Transm (Vienna). 1996;103(10):1187-93. doi: 10.1007/BF01271203.
10
Baseline [(123) I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease.基线 [(123) I]FP-CIT SPECT(DaTSCAN)严重程度与帕金森病患者 3 年内的药物使用相关。
Acta Neurol Scand. 2014 Mar;129(3):204-8. doi: 10.1111/ane.12178. Epub 2013 Aug 20.

引用本文的文献

1
Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.帕金森病治疗的成本效益建模:方法学综述。
Pharmacoeconomics. 2011 Dec;29(12):1025-49. doi: 10.2165/11587110-000000000-00000.
2
Quality of life in patients with Parkinson's disease: Translation and psychometric evaluation of the Iranian version of PDQ-39.帕金森病患者的生活质量:伊朗版PDQ - 39的翻译及心理测量学评估
J Res Med Sci. 2010 Mar;15(2):63-9.
3
Systematic review of the prevalence and incidence of Parkinson's disease in Asia.
亚洲帕金森病患病率和发病率的系统评价。
J Epidemiol. 2009;19(6):281-93. doi: 10.2188/jea.je20081034. Epub 2009 Oct 3.
4
Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.特发性帕金森病患者血小板单胺氧化酶-B活性的改变
Neurochem Res. 2009 Aug;34(8):1427-32. doi: 10.1007/s11064-009-9929-4. Epub 2009 Mar 4.
5
Epidemiology of Parkinson's disease.帕金森病的流行病学
Handb Clin Neurol. 2007;83:129-51. doi: 10.1016/S0072-9752(07)83006-5.
6
Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.罗匹尼罗与左旋多巴治疗帕金森病的成本分析。
Pharmacoeconomics. 2003;21(2):115-27. doi: 10.2165/00019053-200321020-00004.
7
How valid is the clinical diagnosis of Parkinson's disease in the community?社区中帕金森病的临床诊断准确性如何?
J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):529-34. doi: 10.1136/jnnp.73.5.529.
8
Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.帕金森病患者的健康相关生活质量与医疗保健利用:运动波动和异动症的影响
Pharmacoeconomics. 2001;19(10):1013-38. doi: 10.2165/00019053-200119100-00004.
9
Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London.伦敦特发性帕金森病和帕金森综合征的横断面患病率调查。
BMJ. 2000 Jul 1;321(7252):21-2. doi: 10.1136/bmj.321.7252.21.